Part 1 - Case Presentation
Daniel A. Pollyea, MD, MS, presents the case of patient “N.K.” to fellow faculty members Brian A. Jonas, MD, PhD, FACP, and Gabriel N. Mannis, MD. The virtual roundtable panel discusses unique features of the case and explores hypothetical variations of the circumstances, as well as offering insights into how the latest data from clinical trials may impact the future of treatment for patients with acute myeloid leukemia (AML).
Click here to learn more by viewing Part 2 - Case Discussion.
Disclosures:
Brian A. Jonas, MD, PhD, FACP
Consulting Fees: AbbVie, Genentech, GlycoMimetics, Jazz, Takeda
Contracted Research: 47, AbbVie, Amgen, AROG, Celgene, Daiichi-Sankyo, Forma, Genentech/Roche, GMI, Hanmi, Jazz, Pfizer, PCYC
Travel Reimbursement: AbbVie
Gabriel N. Mannis, MD
Consulting Fees: AbbVie, Agios, BMS/Celgene, Genentech, Pfizer
Contracted Research: Gilead/Forty Seven, Glycomimetics, Jazz
Daniel A. Pollyea, MD, MS
Consulting Fees: Celgene, Abbvie, Genentech, Novartis, Karyopharm, Syndax, BMS
Other: Takeda, Syros, Kiadis, Foghorn, Aprea, Gilead, Amgen, Astellas
References:
- Otoukesh S, Zhang J, Nakamura R, Stein AS, Forman SJ, et alI. The efficacy of venetoclax and hypomethylating agents in acute myeloid leukemia with extramedullary involvement. Leuk Lymphoma. 2020 Aug;61(8):2020-2023. doi: 10.1080/10428194.2020.1742908. Epub 2020 Mar 19. PMID: 32191144.
- DiNardo CD, Jonas BA, Pullarkat V, Thirman MJ, Garcia JS, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020 Aug 13;383(7):617-629. doi: 10.1056/NEJMoa2012971. PMID: 32786187.